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INTRODUCTION
Toll-like receptors (TLRs) occupy a
central position in the initiation of cellu-
lar innate immune responses (1). TLRs
can be expressed on the cell surface
(TLR1, -2, -4, -5 -6, -10) or in intracellu-
lar compartments (TLR3, -7, -8, -9), serv-
ing a key role in the early detection of
pathogens. Uncontrolled stimulation of
TLRs potentially can lead to dispropor-
tionate inflammation and tissue injury,
such as may occur during sepsis (2).
Therefore, TLR signaling is tightly regu-
lated to avoid such detrimental inflam-
matory responses. Several negative reg-
ulators of TLRs have been implicated in
preventing excessive TLR signaling, in-
cluding myeloid differentiation pri-
mary-response protein (MyD88), short,
ST2, single-immunoglobulin-interleukin
(IL)-1 receptor-related-molecule (SI-
GIRR), toll-interacting protein (TOL-
LIP), suppressor-of-cytokine signaling
(SOCS), A20 and interleukin-1 receptor
(IL-1R)–associated kinase (IRAK)-M (3).
MyD88 is an adaptor protein essential
for signaling via all TLRs, except TLR3
(1,4). In addition, MyD88 mediates in-
tracellular activation after engagement
of the type I IL-1 receptor and the IL-18
receptor (5). MyD88 initiates intracellu-
lar signaling by recruitment of IRAK-4
and subsequent association and phos-
phorylation of IRAK-1. IRAK-M inhibits
the IRAK-1/IRAK-4 complex and
thereby mitigates intracellular responses
elicited by all MyD88 dependent recep-
tors (6). Accordingly, IRAK-M-deficient
(IRAK-M–/–) macrophages produced
higher levels of proinflammatory cyto -
kines upon stimulation with various
M O L  M E D  1 8 : 1 0 6 7 - 1 0 7 5 ,  2 0 1 2  |  H O O G E R W E R F  E T  A L .  |  1 0 6 7
Interleukin-1 Receptor–Associated Kinase M–Deficient
Mice Demonstrate an Improved Host Defense during
Gram-negative Pneumonia
Jacobien J Hoogerwerf,1,2* Gerritje JW van der Windt,1,2* Dana C Blok,1,2 Arie J Hoogendijk,1,2 Alex F de Vos,1,2
Cornelis van ‘t Veer,1,2 Sandrine Florquin,3 Koichi S Kobayashi,4 Richard A Flavell,5 and Tom van der Poll1,2
1Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center (AMC), 2Center of Experimental and Molecular
Medicine, AMC, and 3Department of Pathology, AMC, University of Amsterdam, Amsterdam, the Netherlands; 4Department of
Cancer Immunology and AIDS, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of
America; and 5Department of Immunobiology and Howard Hughes Medical Institute, Yale University School of Medicine, New
Haven, Connecticut, United States of America 
Pneumonia is a common cause of morbidity and mortality and the most frequent source of sepsis. Bacteria that try to invade
normally sterile body sites are recognized by innate immune cells through pattern recognition receptors, among which toll-like re-
ceptors (TLRs) feature prominently. Interleukin-1 receptor (IL-1R)–associated kinase (IRAK)-M is a proximal inhibitor of TLR signaling
expressed by epithelial cells and macrophages in the lung. To determine the role of IRAK-M in host defense against bacterial
pneumonia, IRAK-M-deficient (IRAK-M–/–) and normal wild-type (WT) mice were infected intranasally with Klebsiella pneumoniae.
IRAK-M mRNA was upregulated in lungs of WT mice with Klebsiella pneumonia, and the absence of IRAK-M resulted in a strongly
improved host defense as reflected by reduced bacterial growth in the lungs, diminished dissemination to distant body sites, less
peripheral tissue injury and better survival rates. Although IRAK-M–/– alveolar macrophages displayed enhanced responsiveness
toward intact K. pneumoniae and Klebsiella lipopolysaccharide (LPS) in vitro, IRAK-M–/– mice did not show increased cytokine or
chemokine levels in their lungs after infection in vivo. The extent of lung inflammation was increased in IRAK-M–/– mice shortly after
K. pneumoniae infection, as determined by semiquantitative scoring of specific components of the inflammatory response in lung
tissue slides. These data indicate that IRAK-M impairs host defense during pneumonia caused by a common gram-negative res-
piratory pathogen.
Online address: http://www.molmed.org
doi: 10.2119/molmed.2011.00450
*JJH and GJWvdW contributed equally to this paper.
Address correspondence to Tom van der Poll, Academic Medical Center, University of
Amsterdam. Meibergdreef 9, Room G2-129, 1105 AZ Amsterdam, the Netherlands. Phone:
+31-20-5665910; Fax: +31-20-6977192; E-mail: t.vanderpoll@amc.uva.nl.
Submitted November 19, 2011; Accepted for publication June 18, 2012; Epub
(www.molmed.org) ahead of print June 18, 2012.
pathogens, TLR ligands or IL-1β (6).
Considering its central position in the
regulation of TLR and IL-1/IL-18 signal-
ing, IRAK-M likely plays an important
role in the host response to bacterial in-
fection. In particular, enhanced IRAK-M
expression has been implicated in the
immune suppression frequently ob-
served in patients with sepsis, a condi-
tion also called LPS tolerance and char-
acterized by a reduced capacity of
immune cells to release proinflamma-
tory cyto kines upon restimulation. In-
deed, IRAK-M–/– cells did not become as
tolerant to LPS upon reexposure to this
 bacterial component as WT cells (6),
whereas our laboratory recently re-
ported that LPS tolerance observed in
healthy humans exposed to intravenous
LPS and in patients with gram-negative
sepsis correlated with enhanced IRAK-M
expression in circulating leukocytes
(7,8). Most importantly, in mice with
polymicrobial abdominal sepsis, en-
hanced IRAK-M expression in pul-
monary macrophages contributed to a
diminished capacity of these cells to re-
spond to Pseudomonas aeruginosa ex vivo,
which resulted in a strongly impaired
host defense response during secondary
(following abdominal sepsis) Pseudo -
monas pneumonia (9).
Current knowledge of the functional
role of IRAK-M in the host response to
invading bacteria and the pathogenesis
of sepsis is highly limited and focused
primarily on its contribution to LPS tol-
erance. Pneumonia is the most common
cause of sepsis by far (2,10). We argued
that IRAK-M could play a pivotal role in
host defense against primary bacterial
pneumonia, considering its expression in
the two most prominent resident cells in
the bronchoalveolar space, that is, macro-
phages and respiratory epithelial cells
(6,9,11,12), and its central place in TLR
signaling. Therefore, here we induced
gram-negative (using Klebsiella pneumo-
niae) pneumonia in IRAK-M–/– and WT
mice, seeking to establish the contribu-
tion of this negative TLR regulator in an-
tibacterial defense in the previously
healthy host.
MATERIALS AND METHODS
Mice
Nine- to 11-wk-old C57BL/6 WT mice
were purchased from Harlan Sprague
Dawley Inc. (Horst, the Netherlands).
IRAK-M–/– mice, backcrossed > 10 times
to a C57BL/6 genetic background were
generated as described (6) and bred in
the animal facility of the Academic Med-
ical Center (Amsterdam, the Nether-
lands). Age and gender matched mice
were used in all experiments.
Study Design and Sample Harvesting
The Animal Care and Use Committee
of the University of Amsterdam ap-
proved all experiments. Pneumonia was
induced as described (13,14). Briefly,
K. pneumoniae serotype 2 (ATCC 43816;
American Type Culture Collection, Man-
assas, VA, USA) was grown for 3 h to
mid-logarithmic phase at 37°C using
Tryptic Soy broth (Difco, Detroit, MI,
USA). Bacteria were harvested by cen-
trifugation at 1,500g for 15 min, and
washed twice in sterile isotonic saline.
Bacteria were then resuspended in sterile
isotonic saline at a concentration of ap-
proximately 104 colony-forming units
(CFUs)/50 μL, as determined by plating
serial 10-fold dilutions on sheep-blood
agar plates. Mice were lightly anes-
thetized by inhalation of isoflurane (Up-
john, Ede, the Netherlands) and bacteria
were inoculated intranasally. In most ex-
periments, mice were euthanized at pre-
defined time points (n = 7–9 per group at
each time point); sample harvesting and
processing, and determinations of bacter-
ial loads and cell counts were done as
described (13,14). Briefly, mice were
anesthetized with Domitor (Pfizer Ani-
mal Health Care, Capelle aan der IJssel,
the Netherlands; active ingredient:
medetomidine) and Nimatek (Eurovet
Animal Health, Bladel, the Netherlands;
active ingredient: ketamine) and eutha-
nized by heart puncture. Blood was col-
lected in tubes containing heparin. Lungs
and spleen were harvested and homoge-
nized in sterile saline (1:5, weight/vol)
using a tissue homogenizer (Biospec
Products, Bartlesville, OK, USA). CFUs
in organ homogenates and blood were
determined from serial dilutions plated
on blood agar plates, incubated at 37°C
for 16 h before colonies were counted.
For bronchoalveolar lavage (BAL), the
trachea was exposed through a midline
incision and BAL fluid (BALF) was har-
vested by instilling and retrieving 2 ×
0.3 mL of sterile phosphate-buffered
saline. Cell counts were determined for
each BALF sample in a hemocytometer
(Beckman Coulter, Fullerton, CA, USA)
and differential cell counts were per-
formed on cytospin preparations stained
with Giemsa stain (Diff-Quick; Dade
Behring AG, Düdingen, Switzerland).
For immunoassays in lung homogenates,
(unlavaged) lungs were excised, weighed
and homogenized in saline (1:5, weight/
vol). Lung homogenates were diluted 1:2
in lysis buffer containing 300 mmol/L
NaCl, 30 mmol/L Tris, 2 mmol/L MgCl2,
2 mmol/L CaCl2, 2 % Triton X-100 and
AEBSF (4-[2-aminoethyl]benzenesulfonyl
fluoride), EDTA-Na2, pepstatin and leu-
peptin (all 8 μg/mL; pH 7.4) and incu-
bated on ice for 30 min and spun down.
Homogenates were centrifuged at 1,500g
at 4°C for 15 min and stored at –20°C
until assays were performed. In separate
studies, mice were followed for up to
10 d and survival was monitored at least
every 12 h (n = 10 per group).
IRAK-M Expression
Lung homogenates were dissolved im-
mediately in RA1 buffer, RNA was iso-
lated as described by the manufacturer
(Bioke, Leiden, the Netherlands) and
 reverse transcribed using oligo dT
(Promega, Leiden, the Netherlands) and
Moloney murine leukemia virus reverse
transcriptase (Invitrogen, Breda, the
Netherlands). Reverse-transcription-
polymerase chain reactions (RT-PCRs)
were performed using LightCycler SYBR
green I master mix (Roche, Mijdrecht, the
Netherlands) and measured in a Light-
Cycler 480 (Roche) apparatus using the
following conditions: 5 min 95°C hot-
start, followed by 40 cycles of amplifica-
tion (95°C for 15 s, 60°C for 5 s, 72°C for
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20 s). For quantification, standard curves
were constructed by PCR on serial dilu-
tions of a concentrated cDNA, and data
were analyzed using LightCycler soft-
ware. Gene expression is presented as
the ratio of the expression of the house-
keeping gene β2-microglobulin (B2M).
Primers were as follows: B2M; 5′-TGGTC
TTTCT GGTGC TTGTC T-3′ and 5′-
ATTTT TTTCC CGTTC TTCAG C-3′,
IRAK-M; 5′-TGCCA GAAGA ATACA
TCAGA CAG-3′ and 5′-TCTAA GAAGG
ACAGG CAGGA GT-3′.
Assays
Myeloperoxidase (MPO), tumor necro-
sis factor (TNF)-α, IL-6, IL-1β, IL-17,
IL-22, keratinocyte-derived cytokine
(KC/CXCL1), macrophage inflammatory
protein 2 (MIP-2/CXCL2), LPS-induced
CXC chemokine (LIX/CXCL5), MIP-3α
(CCL20) and lipocalin 2 levels were de-
termined by enzyme-linked immunosor-
bent assay (ELISA) (MPO; Hycult, Uden,
the Netherlands; all other: R&D Systems,
Abingdon, United Kingdom). Aspartate
aminotransferase (ASAT), alanine amino-
transferase (ALAT) and lactate dehydro-
genase (LDH) were determined with
commercially available kits (Sigma-
Aldrich, Zwijndrecht, the Netherlands),
using a Hitachi analyzer (Roche) accord-
ing to the manufacturer’s instructions.
Pathology
Paraffin lung sections were stained
with hematoxylin and eosin as described
(15), and scored from 0 (absent) to 4 (se-
vere) for the following parameters: inter-
stitial inflammation, endothelialitis,
bronchitis, edema, thrombi, pleuritis and
percentage of the lung surface demon-
strating confluent (diffuse) inflammatory
infiltrate by a pathologist blinded for
groups. The total lung inflammation
score was expressed as the sum of the
scores for each parameter, the maximum
being 28.
Stimulation of Primary Alveolar
Macrophages
Alveolar macrophages were harvested
from IRAK-M–/– and WT mice by bron-
choalveolar lavage (BAL) (n = 8 per
strain) as described (15,16). Cells were
 resuspended in RPMI 1640 containing
2 mmol/L L-glutamine, penicillin, strep-
tomycin and 10% fetal calf serum in a
final concentration of 5 × 104 cells/200 μl.
Cells were then cultured in 48-well mi-
crotiter plates (Greiner, Alphen a/d Rijn,
the Netherlands) for 2 h and washed
with RPMI 1640 to remove nonadherent
cells. Adherent monolayer cells were
stimulated with Klebsiella LPS (L1519,
Sigma, St. Louis, MO, USA; 10 μg/mL),
growth arrested (by treatment with 
mitomycin-C) (Sigma); 50 μg/mL for
60 min at 37°C; 12,5 × 106 CFU/mL) in-
tact K. pneumoniae (MOI 1:100) (17) or
RPMI 1640 for 16 h. Supernatants were
collected and stored at –20°C until as-
sayed for cytokines/ chemokines. (17,18). 
Phagocytosis
Alveolar macrophages were harvested
from WT and IRAK-M–/– mice (n = 8 
per strain) by BAL, washed and resus-
pended in IMDM containing 2 mmol/L
L-glutamine and 10% fetal calf serum to a
 concentration of 25 × 104 cells/mL and
cultured overnight. UV-irradiated
K. pneu moniae were labeled with CFSE
and opsonized with 10% normal mouse
serum (19). Labeled bacteria were incu-
bated with macrophages for 1 h at 37°C
(MOI 100:1) and cells were analyzed
using FACSCalibur (Becton Dickinson,
Breda, the Netherlands). Phagocytosis
index of each sample was calculated: 
median fluorescence of positive cells ×
% positive cells.
Statistical Analysis
All values are expressed as mean ±
SEM. Comparisons for more than two
groups were done with Kruskall-Wallis
followed by Dunn multiple comparison
tests, and other comparisons with Mann-
Whitney U tests. Survival was compared
by Kaplan-Meier analysis followed by a
log-rank test. Analyses were done using
GraphPad Prism version 4.0, GraphPad
Software (San Diego, CA, USA). Values
of P < 0.05 were considered statistically
significant.
RESULTS
IRAK-M Is Induced during Klebsiella
Pneumonia
Knowledge of the expression of
IRAK-M during primary gram-negative
pneumonia is not available. Therefore,
we infected WT mice with K. pneumoniae
via the airways using an established
model of severe pneumonia (13,14) and
determined pulmonary IRAK-M expres-
sion at mRNA and protein level.
IRAK-M mRNA was present at low lev-
els in lungs of uninfected mice and dis-
played strong increases after infection
with K. pneumoniae (Figure 1).
IRAK-M–/– Mice Demonstrate a
Reduced Bacterial Outgrowth and
Dissemination during Klebsiella
Pneumonia
To obtain a first insight into the func-
tional role of IRAK-M in bacterial pneu-
monia, we harvested lungs, blood, spleen
and livers at predefined time points after
infection with K. pneumoniae for quantita-
tive cultures, seeking to collect data repre-
sentative for local defense at the primary
site of infection and subsequent dissemi-
nation and representative for the early 
(3 and 6 h) and late host response (24 and
48 h, that is, just before the first deaths oc-
curred, see below) (Figures 2A–D). In
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Figure 1. IRAK-M is upregulated during
Klebsiella pneumonia. IRAK-M mRNA ex-
pression was determined in lungs of WT
mice before, 24 and 48 h after induction
of pneumonia with live 1 × 104 CFU 
K. pneumoniae. Gene expression is pre-
sented as a ratio of the expression of the
housekeeping gene β2 microglobulin.
Data are expressed as mean ± SEM; n =
7–8/group; *P < 0.05 as compared with 
t = 0. T (or t), time.
lungs, bacterial loads were similar in
IRAK-M–/– and WT mice at 3 h after in-
fection. Remarkably, however, at 6 h,
IRAK-M–/– mice on average had five-fold
lower bacterial counts in their lungs than
WT mice (P < 0.01) and this difference
further increased as the infection pro-
gressed; at 48 h after infection, bacterial
loads were approximately 100-fold lower
in IRAK-M–/– mice when compared with
WT mice (P < 0.05). Cultures of blood,
spleen and liver remained sterile in all
IRAK-M–/– mice and all but one of the WT
mice during the first 6 h. From 24 h on-
ward, the infection had disseminated
from the lungs in all mice, although,
clearly, bacterial loads were lower in
IRAK-M–/– mice in all distant body sites
examined. The strongly reduced bacterial
burdens in blood, spleen and liver also
were reflected in less distant organ dam-
age, that is, the plasma levels of ASAT,
ALAT (indicative of hepatocellular injury)
and LDH (indicative of cellular injury in
general) all were lower in IRAK-M–/– mice
48 h after infection (Figures 3A–C). The
improved host defense of IRAK-M–/– mice
also resulted in a survival advantage:
4/10 IRAK-M–/– mice died during a 10-d
follow-up versus 8/10 WT mice (P = 0.07;
Figure 3D). Together, these data strongly
suggest that IRAK-M impairs antibacter-
ial defense in the lungs upon infection
with Klebsiella, which subsequently results
in enhanced bacterial dissemination and
increased organ injury.
IRAK-M –/– Mice Display Increased
Lung Inflammation but Unaltered
Neutrophil Influx Early after Infection
with Klebsiella via the Airways
Pneumonia results in local inflammation
and inflammatory cell recruitment, which
is an integral part of the host immune re-
sponse (20,21). To obtain insight into the
role of IRAK-M herein, we performed
semiquantitative analyses of lung histol-
ogy slides prepared from IRAK-M–/– and
WT mice 3, 6, 24 and 48 h after infection.
These analyses revealed a gradually devel-
oping histological picture of pneumonia,
as reflected by interstitial inflammation
followed by pleuritis and endothelialitis,
and, in a later stage, bronchitis and edema.
Of interest, IRAK-M–/– mice demonstrated
significantly more lung inflammation
early after infection: both at 3 h (P < 0.05)
and 6 h (P < 0.01), pathology scores were
higher in mice lacking IRAK-M relative to
WT mice (Figures 4A–F). Especially the al-
most doubled inflammation score in
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Figure 2. IRAK-M–/– mice demonstrate reduced bacterial growth and dissemination during
Klebsiella pneumonia. WT (closed symbols) and IRAK-M-deficient (IRAK-M–/–) (open sym-
bols) mice were infected intranasally with 1 × 104 CFU K. pneumoniae and euthanized at
3, 6, 24 and 48 h after induction of pneumonia. Bacterial loads in lung (A), blood (B),
spleen (C) and liver (D) were determined. Data are expressed as mean ± SEM; n = 7–9/
group; *P < 0.05, **P < 0.01 and ***P < 0.001 as compared with WT mice.
Figure 3. IRAK-M–/– mice demonstrate less tissue injury during Klebsiella pneumonia. WT
(closed symbols) and IRAK-M-deficient (IRAK-M–/–) (open symbols) mice were infected in-
tranasally with 1 × 104 CFU K. pneumoniae and euthanized at 6, 24 and 48 h after induction
of pneumonia. ASAT (A), ALAT (B) and LDH (C) in plasma were determined. Dotted lines rep-
resent mean values of healthy mice (n = 4). Data are expressed as mean ± SEM; n = 7–9/
group; *P < 0.05 and **P < 0.01 as compared with WT mice. (D) Survival was observed in WT
(closed symbols) and IRAK-M–/– (open symbols) mice after intranasal infection with 1 × 104
CFU K. pneumoniae. n = 10/group. P value indicates the difference between groups.
IRAK-M–/– mice at 6 h, which, in particular,
was caused by the presence of evident
bronchitis that, in this phase of the infec-
tion, was still absent in all but one WT
mice; in addition, IRAK-M–/– mice dis-
played more extensive endothelialitis and
edema at early time points, which is re-
markable in light of the five-fold lower
bacterial load at this time point (which, in
theory, provided a less potent proinflam-
matory stimulus). At later time points
after infection, (24 and 48 h) pathology
scores had increased considerably in all
animals and were no longer any different
between mouse strains (Figures 4G–L). Of
note, however, at this stage of the infec-
tion, IRAK-M–/– mice had up to 100-fold
fewer bacteria in their lungs, again point-
ing to an inflammation-enhancing effect of
IRAK-M  deficiency.
Considering that neutrophils play an
important role in innate defense early
after Klebsiella airway infection (22,23) and
in light of the early benefit of IRAK-M–/–
mice with regard to pulmonary bacterial
loads, we determined neutrophil counts
in BAL fluid (BALF) harvested from
IRAK-M–/– and WT mice 3 or 6 h after in-
fection (Figure 4M); in addition, we deter-
mined MPO concentrations in whole lung
homogenates, providing insight into the
total neutrophil content of lung tissue
(Figure 4N). These analyses revealed no
differences between groups, indicating
that the lower pulmonary bacterial loads
detected in IRAK-M–/– mice 6 h after in-
fection could not be explained by an ac-
celerated recruitment of neutrophils to the
primary site of infection. During pro-
gressed pneumonia (24 and 48 h after in-
fection), pulmonary MPO concentrations
strongly increased in both groups and sig-
nificantly more so in WT mice (see Fig-
ure 4N), probably as a consequence of the
much higher bacterial burdens in these
animals relative to IRAK-M–/– mice.
IRAK-M Deficiency Does Not Influence
the Capacity of Alveolar Macrophages
to Phagocytsoe Klebsiella
Considering the reduced bacterial
loads in lungs of IRAK-M–/– mice very
early after infection, we were interested
to examine the impact of IRAK-M defi-
ciency on the capacity of alveolar macro-
phages to phagocytose Klebsiella in vitro.
Phagocytosis of Klebsiella by IRAK-M–/–
and WT alveolar macrophages was simi-
lar (Figure 5).
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Figure 4. Enhanced lung histopathology in IRAK-M–/– mice early after induction of Klebsiella
pneumonia. Representative lung histology of WT (A, D, G and J) and IRAK-M–/– (B, E, H
and K) mice at 3 (A–C), 6 (D–F), 24 (G–I) and 48 (J–L) h after intranasal infection with 1 ×
104 CFU K. pneumoniae. The lung sections are representative for 7–9 mice per group per
time point. H&E staining, original magnification 20x. Inflammation scores are expressed as
mean ± SEM (WT mice: black bars; IRAK-M–/– mice: white bars n = 7–9/group). Neutrophil
influx into bronchoalveolar lavage fluid (M) and myeloperoxidase (MPO) concentrations
in lung homogenates (N) at 3 h to 48 h after infection with 1 × 104 CFU of K. pneumoniae.
Data are expressed as mean ± SEM; n = 7–9/group, *P < 0.05, **P < 0.01 as compared
with WT mice.
IRAK-M Deficiency Enhances
Klebsiella-Induced Cytokine and
Chemokine Release by Alveolar
Macrophages Ex Vivo but Does Not
Impact on Mediator Release in Lungs
In Vivo
IRAK-M–/– bone marrow-derived
macrophages have been reported to pro-
duce higher levels of proinflammatory cy-
tokines upon incubation with bacteria such
as Escherichia coli, Salmonella typhimurium
and Listeria monocytogenes (6). To deter-
mine the impact of IRAK-M on cytokine
and chemokine release by alveolar macro-
phages exposed to Klebsiella, we incubated
primary IRAK-M–/– and WT alveolar
macrophages for 16 h with either growth-
arrested K. pneumoniae or LPS derived
from K. pneumoniae, and measured TNF-α,
IL-6, CXCL1 and CXCL2 in culture super-
natants. IRAK-M–/– macrophages released
increased amounts of all four mediators,
although for IL-6 and CXCL2 the differ-
ence with WT cells did not reach statistical
significance (Figures 6A–D). Next, we de-
termined whether IRAK-M deficiency in-
fluences the release of cytokines and
chemokines in the lung during Klebsiella
pneumonia in vivo. First, we focused on
early (3 h and 6 h) mediator release into
the bronchoalveolar space, considering
that alveolar macrophages are the most
prominent resident leukocytes there (Fig-
ures 6E–H). Although the concentrations of
TNF-α, IL-6, CXCL1 and CXCL2  measured
in BALF harvested from IRAK-M–/– mice 
3 h after infection tended to be higher than
those detected in BALF from WT mice, the
differences between groups were not sig-
nificant. At 6 h after infection, TNF-α and
CXCL2 levels were even lower in BALF
obtained from IRAK-M–/– mice as com-
pared to WT mice, indicating that the
lower bacterial burdens in lungs of the for-
mer mouse strain had a greater impact on
mediator release than the absence of
IRAK-M. To more closely study the contri-
bution of the Klebsiella load to pulmonary
cytokine and chemokine concentrations,
we measured TNF-α, IL-6, CXCL1 and
CXCL2 in whole lung homogenates har-
vested 3 to 48 h after infection, spanning
the period of a gradually growing bacter-
ial burden (Figures 6I–L). TNF-α was the
only mediator that displayed high concen-
trations early after infection, decreasing
thereafter. In contrast, the lung levels of
IL-6, CXCL1 and CXCL2 strongly increased
as the infection progressed in WT mice,
and, from 24 h onward, the levels of these
mediators were all lower in IRAK-M–/–
mice. Together these data suggest that the
bacterial load drives the extent of media-
tor production in the lungs, overruling the
possible inhibiting effect of IRAK-M
hereon.
Although IRAK-M expression originally
was considered to be restricted to macro-
phages, recent evidence suggests that
IRAK-M likely also is expressed by respi-
ratory epithelial cells (11,12). To examine a
possible effect of IRAK-M deficiency on
the production of antimicrobial proteins
produced by the respiratory epithelium, we
measured lipocalin 2 and CCL20, which
have been implicated in host defense
against respiratory tract infection (24,25).
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Figure 5. Phagocytosis of Klebsiella by WT
and IRAK-M–/– alveolar macrophages.
Phagocytosis of K. pneumoniae was deter-
mined in alveolar macrophages from WT
(closed symbols) and IRAK-M–/– (open sym-
bols) mice. Data are expressed as mean ±
SEM; n = 8/ group, The difference between
groups was not significant.
Figure 6. Enhanced TNF-α and CXCL1 release by IRAK-M–/– macrophages. TNF-α, IL-6, CXCL1
and CXCL2 concentrations in (A–D) alveolar macrophage supernatants from WT (black
bars) and IRAK-M–/– (white bars) mice after ex vivo incubation with RPMI, LPS from K. pneu-
moniae (LPS KP 10 μg/mL) or growth-arrested K. pneumoniae (GAKP MOI 1:100) for 16 h (n =
4/ group, *P < 0.05 as compared with medium stimulation), (E–H) bronchoalveolar lavage
fluid and (I–L) lung homogenates from WT (black bars/closed symbols) and IRAK-M–/– (white
bars/open symbols) mice 3-48 h after infection with 1 × 104 CFU of K. pneumoniae. Data are
expressed as mean ± SEM; n = 7-9/group, *P < 0.05, **P < 0.01 as compared with WT mice.
Early after infection (3 h and 6 h) lipocalin 2
and CCL20 concentrations did not differ
in BALF obtained from IRAK-M–/– and
WT mice (Figures 7A, B). In lung ho-
mogenates lipocalin 2 and CCL20 levels
were lower in IRAK-M–/– mice as the in-
fection proceeded (Figures 7D, E). To ob-
tain further evidence that IRAK-M defi-
ciency did not enhance the responsiveness
of respiratory epithelial cells in vivo, we
measured CXCL5, a CXC chemokine that
is produced exclusively by epithelial cells
(26,27), in BALF and lung homog enates
and found no differences between 
IRAK-M–/– and WT mice (Figures 7C, F).
Finally, considering that mucosal immu-
nity in the lung during pneumonia regu-
lated at least in part is by Th17 cytokines
(24), we measured IL-17 and IL-22, both of
which have been shown to play a protec-
tive role in the host response to Klebsiella
pneumonia (23,28). However, in both
mouse strains IL-17 and IL-22, levels were
either low or not above baseline concen-
trations in BALF obtained 3 h or 6 h after
infection (data not shown).
DISCUSSION
Pneumonia represents a persistent and
pervasive public health problem. In the
United States, respiratory tract infections
cause more disease and death than any
other infection, and, in the last 50 years,
mortality due to pneumonia has not
changed significantly (29). Rapid recogni-
tion of pathogens that reach the lower res-
piratory tract is essential for an effective
host defense against invading microorgan-
isms (21). IRAK-M inhibits the intracellu-
lar IRAK-1 to IRAK-4 signaling complex,
and, thereby, all MyD88 dependent recep-
tors (6). A recent study implicated MyD88
as an important mediator of a protective
immune response during Klebsiella pneu-
monia (30). Here, we show that IRAK-M
strongly impairs host defense during
pneumonia caused by K. pneumoniae, as
reflected by reduced bacterial growth and
dissemination and diminished distant
organ injury in mice lacking IRAK-M. In
accordance, IRAK-M–/– mice showed a re-
duced mortality (40% versus 80% in WT
mice), although the difference between
groups did not reach statistical signifi-
cance (P = 0.07). Conceivably, larger exper-
imental groups and/or a slightly less se-
vere model using a lower infectious dose
would reveal a statistically significant sur-
vival advantage for IRAK-M–/– mice.
A recent study implicated IRAK-M in
the reduced resistance to secondary pneu-
monia caused by P. aeruginosa in mice suf-
fering from polymicrobial peritonitis (9).
In this investigation (9), nonlethal septic
peritonitis was induced by cecal ligation
and puncture to reproduce the immune-
compromised state that frequently accom-
panies sepsis and that is considered to ren-
der the host more vulnerable to secondary
(nosocomial) infections (2,31,32). Mice
subjected to cecal ligation and puncture
and subsequently infected with
Pseudomonas via the airways showed a
strongly enhanced bacterial growth and
mortality due to the respiratory tract infec-
tion when compared with mice that un-
derwent sham surgery. This vulnerable
phenotype corresponded with enhanced
expression of IRAK-M in lung macro-
phages harvested from mice with polymi-
crobial peritonitis and a strongly reduced
capacity of these cells to release TNF-α
upon incubation with P. aeruginosa. In con-
trast, lung macrophages obtained from
IRAK-M–/– mice with sepsis released more
TNF-α upon exposure to P. aeruginosa,
which was associated with a markedly im-
proved host defense against this nosoco-
mial pathogen (9). As such, this previous
study  expanded knowledge on the role of
IRAK-M in the immune suppression asso-
ciated with sepsis (6–8,33). Thus far, the
involvement of IRAK-M in the innate im-
mune response to primary bacterial pneu-
monia in the previously healthy host re-
mained unexplored.
Here, we used an established model of
primary pneumonia caused by a common
respiratory pathogen in which the bacter-
ial load grows over time at the primary
site of infection, followed by dissemina-
tion to distant body sites and sepsis,
thereby allowing investigation of normal
innate defense mechanisms in the respira-
tory tract in a clinically relevant setting
(13,14). Previous studies have docu-
mented that the complete absence of
MyD88 results in an impaired immune re-
sponse to K. pneumoniae pneumonia (30).
Together with the present results, these
data suggest that the activity of the
MyD88–IRAK-1–IRAK-4 signaling path-
way, missing in MyD88–/– mice and less
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Figure 7. IRAK-M does not affect early epithelial responses. Lipocalin 2, CCL20 and CXCL5
concentrations in (A–C) bronchoalveolar lavage fluid and (D–F) lung homogenates from
WT (black bars/closed symbols) and IRAK-M–/– (white bars/open symbols) mice 3 h to 48 h
after infection with 1 × 104 CFU of K. pneumoniae. Data are expressed as mean ± SEM; n =
7–9/group, *P < 0.05 and **P < 0.01 as compared with WT mice.
inhibited in IRAK-M–/– mice, is a crucial
determinant of antibacterial defense dur-
ing Klebsiella pneumonia. Likely, the influ-
ence of IRAK-M on host defense during
pneumonia involves its action on multiple
MyD88 dependent receptors. Indeed,
MyD88 dependent receptors contributing
to host defense against Klebsiella pneumo-
nia include TLR4 (34,35) and TLR9 (36);
the potential roles of other MyD88 depen-
dent TLRs and the IL-18 receptor have not
been studied thus far, whereas IL-1 did
not play a role of significance (37). Of in-
terest, IRAK-M–/– mice demonstrated re-
duced bacterial loads already very early
after infection, suggesting an effect on
Klebsiella by resident cells. Of note, how-
ever, we did not detect a difference in the
capacity of IRAK-M–/– and WT alveolar
macrophages to phagocytose Klebsiella ex
vivo.
The attenuated growth of bacteria in
the lungs was accompanied by an en-
hanced inflammatory response at the tis-
sue level early after infection (3 h and
6 h), as determined by semiquantitative
scores of specific histological alterations
characteristic for bacterial pneumonia. Al-
though IRAK-M inhibits cytokine and
chemokine production by macrophages
stimulated by bacteria or purified TLR
ligands in vitro (Figure 6) (6,9), IRAK-M
deficiency had little if any effect on the
pulmonary levels of these mediators dur-
ing airway infection in vivo; during late
stages of the infection, cytokine and
chemokine levels were even lower in the
lungs of IRAK-M–/– mice. The strongly re-
duced bacterial loads in IRAK-M–/– mice,
providing a diminished proinflammatory
stimulus to immune cells in the lung, af-
ford a likely explanation for these lower
mediator levels in spite of the absence of
the proximal TLR inhibitor IRAK-M.
These findings differ from those in 
IRAK-M–/– mice with polymicrobial
 peritonitis suffering from secondary
Pseudomonas pneumonia, which showed
increased lung levels of several cytokines
(9). Apparently, the impact of IRAK-M on
cytokine production is more prominent in
the already compromised than in the pre-
viously healthy host. This may, also, at
least in part, explain the fact that IRAK-M
deficiency was associated with enhanced
neutrophil recruitment to the lungs dur-
ing secondary pneumonia following peri-
tonitis (9), whereas it did not influence
neutrophil influx during primary airway
infection (this study). In the current inves-
tigation, IRAK-M deficiency did not en-
hance the production of either lipocalin 2
or CCL20, both antimicrobial proteins
produced by the respiratory epithelium
implicated in host defense against respira-
tory tract infection (24,25). In accordance,
CXCL5, a chemo kine released exclusively
by respiratory epithelial cells (26,27), was
not altered in IRAK-M–/– mice. Of note,
IRAK-M–/– type II alveolar epithelial cells
were reported to release modestly in-
creased amounts of CXCL1 and CXCL2
upon incubation with LPS in vitro (38).
Nonetheless, our current data suggest
that during Klebsiella pneumonia in vivo
IRAK-M deficiency does not affect proin-
flammatory mediator release by respira-
tory epithelial cells to a significant extent.
In a very recent investigation,
IRAK-M–/– mice displayed an exaggerated
inflammatory response in their lungs
upon infection with influenza A virus (38).
In contrast to what we found here, the ex-
tent of lung inflammation in IRAK-M–/–
mice was prolonged over the course of 6 d
and associated with an impaired antiviral
response and increased lethality (38).
Hence, in influenza, pneumonia IRAK-M
serves to prevent detrimental inflamma-
tion thereby facilitating viral clearance.
Clearly, this role is different from the func-
tion of IRAK-M during Klebsiella pneumo-
nia, where the early inhibition of the lung
inflammatory response resulted in en-
hanced bacterial growth and adversely af-
fected outcome. Previous studies confirm
the “double-edged sword” character of in-
nate immunity during lung infection
(39,40), wherein not only aberrant activa-
tion of leukocytes and epithelial cells, but
also of endothelial cells resulting in vascu-
lar hyperpermeability, may contribute to
collateral damage as a consequence of
 innate immune activation (41,42).
WT mice purchased from a commer-
cial supplier (and not littermates) were
used as controls. As such, differences be-
tween IRAK-M–/– and WT mice could
have been caused in part by differences
in composition of the gut microbiome.
Additional studies are warranted to ex-
amine whether IRAK-M deficiency influ-
ences the gut microbiome.
IRAK-M is a negative regulator of TLR
signaling that occupies a crucial role in the
activation of macrophages upon the first
encounter of the immune system with
pathogens. Here, we show that IRAK-M
becomes upregulated rapidly in the lungs
of mice infected with K. pneumoniae via the
airways. Physiologically positioned to in-
hibit potentially damaging lung inflamma-
tion, IRAK-M dampens the early antibac-
terial response during Klebsiella
pneumonia as reflected by lower bacterial
counts in IRAK-M–/– mice from 6 h after
infection onward. 
CONCLUSION
Our study is the first to demonstrate a
function for IRAK-M in host defense
against respiratory tract infection in the
previously healthy host. Preliminary ex-
periments performed by our laboratory in-
dicate that IRAK-M also impairs host de-
fense during gram-positive pneumonia
(data not shown). Together these data
identify IRAK-M as a possible therapeutic
target in the treatment of bacterial respira-
tory tract infection.
ACKNOWLEDGMENTS
We thank Joost Daalhuisen, Marieke
ten Brink and Regina de Beer for expert
technical assistance. JJ Hoogerwerf, 
GJW van der Windt, DC Blok and 
AJ Hoogendijk were supported by insti-
tutional research grants from the Aca-
demic Medical Center, Amsterdam. 
RA Flavell is an Investigator of the How-
ard Hughes Medical Institute.
DISCLOSURE
The authors declare they have no
competing interests as defined by Molec-
ular Medicine, or other interest that
might be perceived to influence the re-
sults and discussion reported in this
paper.
1 0 7 4 |  H O O G E R W E R F  E T  A L .  |  M O L  M E D  1 8 : 1 0 6 7 - 1 0 7 5 ,  2 0 1 2
R O L E  O F  I R A K - M  I N  G R A M - N E G A T I V E  P N E U M O N I A
REFERENCES
1. Beutler BA. (2009) TLRs and innate immunity.
Blood. 113:1399–407.
2. van der Poll T, Opal SM. (2008) Host-pathogen
interactions in sepsis. Lancet Infect. Dis. 8:32–43.
3. Liew FY, Xu D, Brint EK, O’Neill LA. (2005) Neg-
ative regulation of toll-like receptor-mediated
immune responses. Nat. Rev. Immunol. 5:446–58.
4. Ishii KJ, Koyama S, Nakagawa A, Coban C,
Akira S (2008) Host innate immune receptors
and beyond: making sense of microbial infec-
tions. Cell Host Microbe. 3:352–63.
5. Dinarello CA. (2009) Immunological and inflam-
matory functions of the interleukin-1 family.
Annu. Rev. Immunol. 27:519–50.
6. Kobayashi K, et al. (2002) IRAK-M is a negative
regulator of Toll-like receptor signaling. Cell.
110:191–202.
7. van ‘t Veer C, et al. (2007) Induction of IRAK-M
is associated with lipopolysaccharide tolerance
in a human endotoxemia model. J. Immunol.
179:7110–20.
8. Wiersinga WJ, et al. (2009) Immunosuppression as-
sociated with interleukin-1R-associated-kinase-M
upregulation predicts mortality in Gram-negative
sepsis (melioidosis). Crit. Care Med. 37:569–76.
9. Deng JC, et al. (2006) Sepsis-induced suppression
of lung innate immunity is mediated by IRAK-M.
J. Clin. Invest. 116:2532–42.
10. Annane D, Bellissant E, Cavaillon JM. (2005) Sep-
tic shock. Lancet 365:63–78.
11. Balaci L, et al. (2007) IRAK-M is involved in the
pathogenesis of early-onset persistent asthma.
Am. J. Hum. Genet. 80:1103–14.
12. Lagler H, et al. (2009) TREM-1 activation alters
the dynamics of pulmonary IRAK-M expression
in vivo and improves host defense during pneu-
mococcal pneumonia. J. Immunol. 183:2027–36.
13. Rijneveld AW, et al. (2004) Thrombomodulin mu-
tant mice with a strongly reduced capacity to gen-
erate activated protein C have an unaltered pul-
monary immune response to respiratory pathogens
and lipopolysaccharide. Blood. 103:1702–9.
14. Renckens R, et al. (2007) Plasminogen activator
inhibitor type 1 is protective during severe
Gram-negative pneumonia. Blood. 109:1593–601.
15. Knapp S, et al. (2004) Toll-like receptor 2 plays a
role in the early inflammatory response to murine
pneumococcal pneumonia but does not contribute
to antibacterial defense. J. Immunol. 172:3132–8.
16. Wiersinga WJ, et al. (2007) Toll-like receptor 2
 impairs host defense in gram-negative sepsis
caused by Burkholderia pseudomallei (Melioido-
sis). PLoS Med. 4:e248.
17. Wiersinga WJ, Wieland CW, Roelofs JJ, van der
Poll T. (2008) MyD88 dependent signaling con-
tributes to protective host defense against Burk-
holderia pseudomallei. PLoS One. 3:e3494.
18. van der Windt GJ, van ’t Veer C, Florquin S, van
der Poll T. (2010) CD44 deficiency is associated
with enhanced Escherichia coli-induced proin-
flammatory cytokine and chemokine release by
peritoneal macrophages. Infect. Immun. 78:115–24.
19. van der Windt GJ, et al. (2011) Osteopontin im-
pairs host defense during pneumococcal pneu-
monia. J. Infect. Dis. 203:1850–8.
20. Strieter RM, Belperio JA, Keane MP. (2002) Cy-
tokines in innate host defense in the lung. J. Clin.
Invest. 109:699–705.
21. Mizgerd JP. (2008) Acute lower respiratory tract
infection. N. Engl. J. Med. 358:716–27.
22. Tsai WC, et al. (1998) Lung-specific transgenic ex-
pression of KC enhances resistance to Klebsiella
pneumoniae in mice. J. Immunol. 161:2435–40.
23. Ye P, et al. (2001) Requirement of interleukin 17
receptor signaling for lung CXC chemokine and
granulocyte colony-stimulating factor expression,
neutrophil recruitment, and host defense. J. Exp.
Med. 194:519–27.
24. Kolls JK, McCray PB Jr, Chan YR. (2008) Cyto -
kine-mediated regulation of antimicrobial pro-
teins. Nat. Rev. Immunol. 8:829–35.
25. Chan YR, et al. (2009) Lipocalin 2 is required for
pulmonary host defense against Klebsiella infec-
tion. J. Immunol. 182:4947–56.
26. Jeyaseelan S, et al. (2005) Induction of CXCL5
during inflammation in the rodent lung involves
activation of alveolar epithelium. Am. J. Respir.
Cell Mol. Biol. 32:531–9.
27. Cai S, Zemans RL, Young SK, Worthen GS,
Jeyaseelan S. (2009) Myeloid differentiation pro-
tein-2-dependent and -independent neutrophil
accumulation during Escherichia coli pneumo-
nia. Am. J. Respir. Cell Mol. Biol. 40:701–9.
28. Aujla SJ, et al. (2008) IL-22 mediates mucosal host
defense against Gram-negative bacterial pneu-
monia. Nat. Med. 14:275–81.
29. Armstrong GL, Conn LA, Pinner RW. (1999) Trends
in infectious disease mortality in the United States
during the 20th century. JAMA. 281:61–6.
30. Cai S, Batra S, Shen L, Wakamatsu N, Jeyaseelan S.
(2009) Both TRIF- and MyD88-dependent signal-
ing contribute to host defense against pulmonary
Klebsiella infection. J. Immunol. 183:6629–38.
31. Volk HD, Reinke P, Docke WD. (2000) Clinical
 aspects: from systemic inflammation to ‘immu -
noparalysis’. Chem. Immunol. 74:162–77.
32. Hotchkiss RS, Karl IE. (2003) The pathophysiology
and treatment of sepsis. N. Engl. J. Med. 348:138–50.
33. Liu ZJ, et al. (2008) Up-regulation of IRAK-M is
essential for endotoxin tolerance induced by a
low dose of lipopolysaccharide in Kupffer cells.
J. Surg. Res. 150:34–9.
34. Branger J, et al. (2004) Role of Toll-like receptor 4
in gram-positive and gram-negative pneumonia
in mice. Infect. Immun. 72:788–94.
35. Schurr JR, et al. (2005) Central role of toll-like re-
ceptor 4 signaling and host defense in experi-
mental pneumonia caused by Gram-negative
bacteria. Infect. Immun. 73:532–45.
36. Bhan U, et al. (2007) TLR9 is required for protec-
tive innate immunity in Gram-negative bacterial
pneumonia: role of dendritic cells. J. Immunol.
179:3937–46.
37. Tanabe M, et al. (2005) Compensatory response of
IL-1 gene knockout mice after pulmonary infec-
tion with Klebsiella pneumoniae. J. Med. Micro-
biol. 54:7–13.
38. Seki M, et al. (2010) Critical role of IL-1 receptor-
associated kinase-M in regulating chemokine-
 dependent deleterious inflammation in murine
influenza pneumonia. J. Immunol. 184:1410–8.
39. Le Goffic R, et al. (2006) Detrimental contribution of
the Toll-like receptor (TLR)3 to influenza A virus-
induced acute pneumonia. PLoS Pathog. 2:e53.
40. Si-Tahar M, Touqui L, Chignard M. (2009) Innate
immunity and inflammation—two facets of the
same anti-infectious reaction. Clin. Exp. Immunol.
156:194–8.
41. Wang S, et al. (2010) Influenza virus-cytokine-
protease cycle in the pathogenesis of vascular hy-
perpermeability in severe influenza. J. Infect. Dis.
202:991–1001.
42. Teijaro JR, et al. (2011. Endothelial cells are cen-
tral orchestrators of cytokine amplification dur-
ing influenza virus infection. Cell. 146:980–91.
R E S E A R C H  A R T I C L E
M O L  M E D  1 8 : 1 0 6 7 - 1 0 7 5 ,  2 0 1 2  |  H O O G E R W E R F  E T  A L .  |  1 0 7 5
